On January 24th, the FDA approved the New Drug Application (NDA) from the U.S. Food and Drug Administration (FDA), for its once-daily MOXATAG(TM) Tablets 775 mg (amoxicillin extended-release tablets) for the treatment of adults and pediatric patients 12 years and older with pharyngitis and/or tonsillitis secondary to Streptococcus pyogenes (commonly referred to as strep throat).
News Release: FDA Approves MiddleBrook’s Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
The company is [[MBRK]] It is obvious from the chart that the market liked this news.
The next day, the company issued a private placement of 21 million.
On February 14th, the company announced this: MiddleBrook Pharmaceuticals Engages Morgan Stanley in Its Strategic Process
The stock traded above $6.50 in September of 2006. On the chart, the 50 day has been beneath the 200 day for a year, but has now created a Golden Cross. It looks like it wants to trade higher until the buyout momentum subsides, or until it is actually bought.
FD: Long MBRK
Not impressed.
Try again.
Aren’t impressed? What about the catchy headline?
Don’t hate.
Have your kids ever had strep throat?
What about not putting the symbol or name of the company in the headline so that readers have to click?
Damn, Fly, I’m trying to drive traffic to help pay for those egregious bandwith fees.
All the time. I have 3 kiddies.
One has the flu, right now.
That’s because you made him practice tennis, in the snow.
I’m surprised that Duc hasn’t ventured over here for a comment on this one.
Wood,
Sorted.
jog
Duc, must be more British colloquialisms.
Sorted?
Wood,
As you have adopted “ta” I have provided you with as you say, further colloquialisms.
Sorted = it’s done
jog
Wood,
I’ve had a quick squizzy at the fundamentals….hideous, as I’m sure you realized.
The research uses *Endpoints*
This is not really the research protocol that I like to see in medicine.
There is some other stuff I want to research, so I’ll get back to you on this as-and-when.
jog
Yeah, my glance at the fundies showed them to be hideous. Just wanted to be sure I hadn’t missed anything.
Of course this is a speculative swing trade, based on the momentum generated from the NDA and buyout rumors, as represented in a nice breakout from a flag.
However, the drug itself interests me, so I’m very curious as to what you find.
Just FYI — if they’ve “engaged” MoStan two weeks ago, it could be quite some time before they announce any kind of deal, even if one is forthcoming.
Announcing you’re for sale is usually considered something of a desperation play in the M&A biz. The buyers will be looking, but with a jaundiced eye.
The “juice” as Fly calls it, might already be out of this sucker…
I have four kids, positive side — they don’t get nasty shit like strep.
Negative side — none of them are older than 12, so they can’t use this stuff anyway.
Doubt any of the Fly’s kids are over 12 either, unless he knocked up some senior at Stella Maris in his wild days.
Jake, thanks for your input. The chart shows there is juice left, imo, but I understand your point.
I don’t expect them to get bought while I’m holding. I just want the momo.
They are either in trials for under 12 or applying to enter trials.
Just admit it, Wood.
You like this stock because it’s “all about” the old fuckers for you.
Pump and Dump!
ZING!
Srsly though. Turrible.
I thought we got done with sub-$5/$10 stocks with MVIS…
Fuck everyone on this thread, except Duc, although he will probably rip it up when he gets done trading his GS for the day.
Seriously though, there is not a technical analyst here that can argue that the technicals do not look GREAT.
Wood,
Could be a winner…
IMS collects pharmaceutical sales data from markets across the world. As of January 2007, they collect sales data from 75% of prescriptions in 100 countries around the world. In the U.S. they are able to cover 90% of pharmaceutical sales. This allows IMS to cover over one million pharmaceutical products from over 3,000 companies.[1]
IMS also uses their own data to produce syndicated reports such as market forecasts. These predict how a market in a specific country or specific therapy area will change over time. This works through the production of baseline projections of sales and the application of different future events to this baseline to produce a forecast.
The consulting arm of IMS works on customised projects for the pharmaceutical industry. An example of how this might work would be if a new product was being developed by a pharmaceutical company they would want to know what an acceptable price would be for the product. IMS would attempt to give an idea of what might be acceptable through the use of market research (interviews with physicians, pharmacists and regulatory bodies) whilst also looking at other product launches of similar (analogous) products. This brings together IMS’s sales data and primary research in the form of interviews to create a picture of what a government may be prepared to pay for a new, innovative drug.
What IMS say;
According to data from IMS Health, a pharmaceutical research company, approximately one-quarter of amoxicillin prescriptions are written for pharyngitis, strep throat, and tonsillitis in adults and children. Approximately 60 million prescriptions for amoxicillin were written in 2006 with total retail sales of more than $650 million. For pediatricians, amoxicillin is the most prescribed drug among all therapeutic classes. Among family physicians, amoxicillin is the twelfth most prescribed drug among all therapeutic classes.
The most commonly prescribed treatment for the management of Group A streptococcal pharyngitis is 500 milligrams of amoxicillin dosed three-times daily for a period of 10 days. With the FDA approval of MOXATAG, physicians now have available the first once-daily product in the aminopenicillin class for the treatment of pharyngitis while utilizing approximately one-half the amount of amoxicillin currently used.
The one [minor fly in the ointment] is the use of *Endpoints*
However, this drug has been used for years [decades] so I guess endpoints are actually acceptable…just poor quality research
jog
I’m sorry but a spec biotech is a spec biotech with or without fundies. that’s me though. nice hw duc.
Thanks Duc. I had found the IMS data, and actually, more so than the technicals, that was why I bought the stock.
Danny, quiting hating, hater. Pah.
Wood,
Interesting outcome then.
Potentially robust sales going forward, but, never easy to break into medical market, expensive, as the sales force have to overcome doctor loyalty/inertia.
Quality of management becomes really crucial in these types of situations.
Quick link to Insider Sales/Purchases
http://moneycentral.msn.com/investor/invsub/insider/trans.asp?Symbol=MBRK
So the next question…How many Options has the senior management been awarding themselves. Here you’ll have to go to the Financials to get the information.
If they are overly generous, which it looks like as the CEO has been dumping shares @ below $1.50, they [management] must be considered greedy…thus they will shaft shareholders.
To get a true picture, I’d have to crunch all the numbers and see where else they have been profilgate with shareholder funds.
For an *old* compound, they’ve spent [lost] a load of capital.
jog
If you bought at 3.50 breakout and you’re not selling some at 4 two days later, I want some of what you’re smoking. Unless it’s paint chips.
you can’t deny that these stocks are notoriously homo.
though I commend the hw, find, and good trade shed. not hatin, just sayin. You kno tha game.
so i’ll end with this — great breakout play.
Danny, thanks. But you know I was just gettin’ your goat, right?
I bought at 3.55, looking at 4.20 right now, and haven’t sold any as I’m at work, and that would require me to call my wife to place the trade. I’m thinking I let it ride, and look at a limit sell in the a.m.
Shed, did you get stopped out of your CPHD today?
of course I know that! seriously though it was a good trade
No Boca I did not get stopped out but I instantly thought of you this a.m. when I was able to get a quote at around 10:15. It was down almost 2 bucks. I thought, WTF? And then I thought about you. Gay, I know. Anyway…
I’m not sure what I’ll do in the morning. I’m off work tomorrow so I can trade freely. I may just let it ride.
Actually, I just checked AHs, and it is UP .88??
Problem is that I’ve followed the company for 7 years now. It was the first stock I ever bought. There is sentimental history. However, I will not be married to it.
hahaha I thought about you too today when I saw at one point it was down just over $2.
I sold my shares recently so didn’t have to worry today. But I had to wonder what’s up, down more than 5 percent on no news? Or maybe the news just hasn’t come out yet. I’m keeping an eye on it for another trade.
BTW you’re on a roll, a strep throat stock and a MRSA stock… what’s next, GILD?
Sweet call.
Thanks Boca and Fly.
Still deciding what to do with my MBRK. I’ve sold too early during moves like this before.
Figured I’d do more research.
There have been some interesting filings, in the past couple of weeks. Bear Stearns is one tute involved. Check out the 13Gs and recent Form 4s.
http://yahoo.brand.edgar-online.com/default.aspx?cik=1161924
Wood,
Currently I am locked out of my own blog.
Not only does GOOG hate me, but now, seemingly, wordpress also.
Send me an e-mail regarding GS tomorrow.
jog
Wood,
New link
http://leduc998.wordpress.com/
They’re releasing results before the market opens Tuesday. I find the timing somewhat encouraging. End of the week Friday news/results dumps are common for smallish companies if they have bad results/news to hide, they’re hanging it out there. I think it runs right through Monday and into the release.
MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK – News), a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced it will release results for the quarter and fiscal year ended December 31, 2007, on Tuesday, March 4, 2008, before the market opens. A full text copy of the release will be disseminated at that time.
Well, we will see some of the unsuccessful ones in alcohol rehabilitation after the new year probably… But let us think pink…
So the the young 22yr old “Josh” pumping LTUS was “Ducati”.
Hey Bartender, Joe Boo needs a refill.
No, and pumping implies I recommended you buy.
I did not.
I would not.
I only said what I was doing. Someone asked me not to comment any more, and I stopped doing that too.